The Boston investor backs the clinical stage biotechnology firm to advance its immune-resetting therapies.
"We have two clinical stage drug product candidates, '1805 and '1104, that have demonstrated impressive efficacy and safety data in phase 2a clinical studies on Rheumatoid Arthritis and Allergic Disease respectively and we are delighted to have Morningside as a partner to advance our programs,"
The Series B round was led by Deutsche Bank alongside participation from Deutsche Börse and Citi.
"We’re delighted to enjoy the confidence of these premier global institutions and to give them an important voice on our Board of Directors as we continue on our exciting growth trajectory. During this unprecedented period of global turmoil and market volatility, it speaks volumes for the CloudMargin business model, achievements and strategy that we were able to successfully close this meaningful investment round with such high calibre partners as Deutsche Bank, Deutsche Börse and Citi. For financial services institutions, the impact of COVID-19 has further reinforced our value proposition by highlighting many challenges the industry has faced for a prolonged period and acting as a catalyst to drive transformational change; firms are placing a strategic priority on adopting modern, Software-as-a-Service based cloud technologies that provide agility as well as operational and cost efficiencies."
The company completed the largest convertible round in UK crowdfunding history in under 48 hours.
"This round means big things for Chip. The growth we’ve seen this year has been incredible, but it’s time to take the business to the next level. Right now we are presented with a huge opportunity to capture a slice of Europe’s €30 trillion savings market that’s ripe for disruption, and Chip is poised ready to accelerate and dominate this space as a market-defining savings and wealth management app."